EGFR and non-small cell lung carcinoma: However, despite the initial efficacy of first-generation EGFR TKIs, nearly all NSCLC patients eventually develop resistance to these drugs within 10–14 months, primarily due to the emergence of the EGFR mutation, T790M (Wu and Shih, 2018).